EGFR inhibitors
Provided herein are compounds, salts, solid forms, and pharmaceutical compositions that are related to EGFR inhibitors, such as N-(2-((2-(dimethylamino)ethyl)(methyl)amino)-4-methoxy-5-((4-(1-(2,2,2-trifluoroethyl)-1H-indol-3-yl)pyrimidin-2-yl)amino)phenyl)acrylamide, as well as methods of preparing the same. Also provided herein are methods of using the compounds, salts, solid forms, and pharmaceutical compositions for the treatment of diseases or disorders, such as cancer.
1. A method of preparing Compound 4, or a pharmceutically acceptable salt thereof,
the method comprising:
1) converting Compound 1, or a salt thereof, into a compound of Formula III, or a salt thereof, under an amide formation condition, wherein Lg in Formula III is a leaving group;
2) converting the compound of Formula III, or a salt thereof, into Compound 4 under an elimination reaction condition; and optionally,
3) reacting Compound 4 with a suitable acid to form a pharmaceutically acceptable salt of Compound 4.
2. The method of claim 1 , wherein Lg in Formula III is a halide or an oxygen containing leaving group.
3. The method of claim 1 , wherein Lg in Formula III is Cl.
4. The method of claim 1 , wherein converting Compound 1 into the compound of Formula III, or a salt thereof, comprises reacting Compound 1 with an acyl chloride reagent having Formula IV, wherein Lg is a leaving group:
5. The method of claim 4 , wherein Lg in Formula IV is Cl.
6. The method of claim 1 , wherein converting the compound of Formula III, or a salt thereof, into Compound 4 comprising contacting the compound of Formula III with a base.
7. The method of claim 1 , wherein Compound 1 is prepared by a process comprising reducing Compound A9 with H2 in an ether solvent in the presence of a catalyst:
8. A compound of Formula III, or a salt thereof:
wherein Lg is a leaving group.
9. The compound of claim 8 , or a salt thereof, wherein Lg is Cl or OH.